Apixaban Dosing Guidelines for Patients with Renal Impairment

Introduction to Apixaban Dosing

The American College of Cardiology recommends a standard dose of 5 mg twice daily for patients with atrial fibrillation, with a reduced dose of 2.5 mg twice daily for patients with ≥2 of the following criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (or CrCl 15-29 mL/min) 1, 2, 3
For acute venous thromboembolism (VTE) treatment, the standard loading dose is 10 mg twice daily for 7 days, followed by a maintenance dose of 5 mg twice daily 1, 4

Patients with severe chronic kidney disease (CrCl 15-29 mL/min) should receive a reduced maintenance dose of 2.5 mg twice daily 3, 5
The U.S. FDA guidance recommends a dose of 5 mg twice daily for patients with end-stage renal disease (CrCl <15 mL/min or dialysis), reduced to 2.5 mg twice daily only if age ≥80 years or weight ≤60 kg 2

Calculate creatinine clearance (CrCl) using the Cockcroft-Gault formula with actual body weight, and reassess renal function at least annually or more frequently if clinically indicated 1, 2
Monitor patients for bleeding signs, particularly during the loading phase, and adjust the dose as needed 3, 4

P-glycoprotein inhibitors (e.g., verapamil, dronedarone, ketoconazole) can increase apixaban levels, and more conservative dosing may be necessary during the maintenance phase 4
Apixaban has a similar or lower bleeding rate compared to warfarin in patients with advanced chronic kidney disease (CKD) stages 4-5, but rare hemorrhagic complications can occur even with guideline-based dosing 4

In patients with estimated creatinine clearance greater than 30 mL/min, no renal‑function‑based dose reduction of apixaban is required unless other standard dose‑reduction criteria are met (age ≥80 years, body weight ≤60 kg, serum creatinine ≥1.5 mg/dL). This recommendation is derived from the pivotal clinical trial data used for FDA labeling. 6

Apixaban is eliminated via the kidneys to a lesser extent (approximately 27 % renal clearance) compared with dabigatran (≈80 %) and rivaroxaban (≈35 %), contributing to a more favorable safety profile in patients with renal impairment. This pharmacokinetic comparison is reported in the same European Heart Journal analysis. 6

Stage 3 CKD (CrCl 30‑59 mL/min): Use the standard dose of apixaban 5 mg twice daily; if a patient meets ≥ 2 of the following criteria—age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL—reduce to 2.5 mg twice daily. American College of Cardiology recommendation. 7
Stage 4 CKD (CrCl 15‑29 mL/min): Give apixaban 2.5 mg twice daily to all patients; renal impairment alone mandates this dose reduction. American College of Cardiology recommendation. 7
Stage 5/ESRD (CrCl < 15 mL/min, dialysis): FDA‑approved regimen is apixaban 5 mg twice daily, reduced to 2.5 mg twice daily only when the patient is ≥ 80 years old OR weighs ≤ 60 kg (a single criterion is sufficient). American College of Cardiology recommendation. 7

Dose adjustment for warfarin: In severe CKD, warfarin dosing must be reduced by roughly 20 % relative to apixaban dosing. American College of Cardiology observation. 7
Vascular calcification risk: Warfarin therapy is linked to increased vascular calcification because it inhibits Matrix Gla Protein activity. American College of Cardiology finding. 7
Anticoagulant‑related nephropathy: CKD patients on warfarin experience anticoagulant‑related nephropathy about twice as often as those on apixaban. American College of Cardiology data. 7
Time in therapeutic range (TTR): Warfarin-treated CKD patients have a lower TTR, which translates into a higher incidence of stroke, major bleeding, and mortality compared with apixaban. American College of Cardiology analysis. 7